Pfizer PFE is set to release its fourth-quarter and full-year 2025 results on Feb. 3, with investor attention focused on ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

In early January 2026, Pfizer Inc. and Boltz, PBC announced a collaboration to apply biomolecular AI foundation models to ...

PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on ...

Pfizer PFE reported second-quarter 2025 adjusted earnings per share of 78 cents, which comprehensively beat the Zacks Consensus Estimate of 58 cents per share. Earnings rose 30% year over year.

* Pfizer and Astellas have a clinical collaboration agreement with Merck to evaluate the combination of PADCEV ® and KEYTRUDA ® in patients with previously untreated metastatic urothelial cancer. ** ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the ...

Pfizer PFE and AbbVie ABBV are both U.S. pharmaceutical giants with a strong leadership position in various therapeutic areas. For Pfizer, oncology sales comprise around 28% of its total revenues.

Pfizer has taken a beating in recent years, and its market cap is now around $140 billion. But with the company still ...